The "https://www.aecc.es" Spanish Cancer Association will fund 18,000 euros for the project “MicroRNA-based therapy for high-risk Neuroblastoma”, led by Dr. Miguel Francisco Segura, from the Laboratory of Translational Research in Pediatric Cancer. The aim of the research is to restore the sensibility to chemotherapy in Neuroblastoma, using microRNAs.Neuroblastoma (NBL) is the most common solid tumor of infancy. Nearly 45% of all children with this type of tumor are designated as high-risk patients and 60% of them die, mainly due to resistance to therapy and metastasis. Recently, it has become evident that non-coding RNA, in particular microRNAs (miRNAs) play a fundamental role during development and tissue homeostasis, and have been shown to be deregulated in numerous diseases including cancer. Therefore, the restoration of miRNA levels can be the basis for novel forms of therapy, by limiting the aggressive potential of NBL tumor cells and/or enhancing their sensitivity to current forms of treatment.Dr. Segura collected the grant at the 'Nit Solidaria' for collecting funds for cancer research. Besides this VHIR’s project, the cancer association will also fund four more projects related with the oncology research.